Abstract
BackgroundThis trial was conducted as part of a project that aims to enhance public understanding and use of research in decisions about healthcare by enabling viewers to participate in research and to follow the process, through television reports and on the web. Valerian is an herbal over-the-counter drug that is widely used for insomnia. Systematic reviews have found inconsistent and inconclusive results about its effects.MethodsParticipants were recruited through a weekly nationally televised health program in Norway. Enrolment and data collection were over the Internet. 405 participants who were 18 to 75 years old and had insomnia completed a two week diary-keeping run-in period without treatment and were randomised and mailed valerian or placebo tablets for two weeks. All participants and investigators were blind to treatment until after the analysis was completed.FindingsFor the primary outcome of a minimally important improvement in self-reported sleep quality (≥0.5 units on a 7 point scale), the difference between the valerian group (29%) and the placebo group (21%) was not statistically significant (difference 7.5%; 95% CI-0.9 to 15.9; p = 0.08). On the global self-assessment question at the end of the treatment period 5.5% (95% CI 0.2 to 10.8) more participants in the valerian group perceived their sleep as better or much better (p = 0.04). There were similar trends favouring the valerian group for night awakenings (difference = 6.0%, 95% CI-0.5 to 12.5) and sleep duration (difference = 7.5%, 95% CI-1.0 to 16.1). There were no serious adverse events and no important or statistically significant differences in minor adverse events.InterpretationBased on this and previous studies, valerian appears to be safe, but with modest beneficial effects at most on insomnia compared to placebo. The combined use of television and the Internet in randomised trials offers opportunities to answer questions about the effects of health care interventions and to improve public understanding and use of randomised trials.Trial RegistrationControlled-Trials.com ISRCTN72748991
Highlights
This trial of the effectiveness of valerian for insomnia was conducted as part of a collaboration between the Norwegian Knowledge Centre for the Health Services and the Norwegian Broadcasting Corporation (NRK) television program, ‘‘Puls’’
There were similar trends favouring the valerian group for night awakenings and sleep duration
We did not achieve our pre-trial intended sample size, we are able to rule out the possibility that valerian has a large beneficial effect
Summary
This trial of the effectiveness of valerian for insomnia was conducted as part of a collaboration between the Norwegian Knowledge Centre for the Health Services and the Norwegian Broadcasting Corporation (NRK) television program, ‘‘Puls’’. The study was used as an example of a randomised trial in explaining to the television audience some of the principles related to such studies. In this study we excluded people who reported symptoms of secondary insomnia This trial was conducted as part of a project that aims to enhance public understanding and use of research in decisions about healthcare by enabling viewers to participate in research and to follow the process, through television reports and on the web. Based on this and previous studies, valerian appears to be safe, but with modest beneficial effects at most on insomnia compared to placebo.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
